Oligonucleotide analogues targeting human LMNA

US11802283B2 · kind B2 · utility

Assignees

• Sarepta Therapeutics, Inc. · US
• The United States of America as Represented by the Secretary, Dept. of Health and Human Services · US
• University of Maryland · US
• The Progeria Research Foundation · US

Inventors

• Michael R. Erdos · Bethesda, US
• Francis S. Collins · Rockville, US
• Kan Cao · Bowie, US
• Ryszard Kole · Chapel Hill, US
• Richard K. Bestwick · Corvallis, US
• Leslie B. Gordon · Foxborough, US

Key dates

• Filing date: Sep 17, 2020
• Grant date: Oct 31, 2023
• Expiry date: Nov 9, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/33
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

Provided are LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.